Ingo Hartung/LinkedIn
Apr 26, 2025, 16:47
Ingo Hartung: Excellent educational talk about ADC design aspects by Rafaele Colombo at AACR25
Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, shared a post on X:
“Another excellent educational talk about ADC design aspects at AACR25 by Rafaele Colombo.
Linking payload potency and linker stability to clinical observations. Well, it remains complex to deduce generalizable design principles.
Understanding payload fate is crucial.”
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Debunking 2 myths:
More potent payload ≠ better ADC
More stable ≠ better ADC
Highly potent payloads have proven to be too toxic. Highly stable ADCs have been found associated with unexpected side effects (eg. ocular).
Balance is key.
Terrific presentation by Raffaele Colombo”
More posts featuring AACR25
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 19, 2025, 01:43
May 18, 2025, 13:40
May 18, 2025, 13:31
May 18, 2025, 12:54